INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

NCT04455841 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis

Interventions

DRUG: INCB000928
DRUG: ruxolitinib

Sponsor

Incyte Corporation